Trial reportThe oncologist2023
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
Trial report in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00078949 (Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab vs Observation
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Experiences and coping strategies of time toxicity in young and middle-aged patients with lymphoma: a descriptive qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- The experience of time toxicity in cancer patients: a meta-synthesis of qualitative research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Healthcare contact days in cancer survivors relative to those with no cancer history.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Planned time burden for patients participating in phase 2 cancer trials.The oncologist · 2026Article
- Accuracy of patient, care partner, and clinician health care contact day recall.The oncologist · 2026Article
- Article
- A novel patient-centered outcome in cancer care, days at home: a scoping review and guide for its future use.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer.JNCI cancer spectrum · 2026Article
- Characterizing and Addressing the Financial, Time, and Administrative Burdens of Cancer and its Care.Current treatment options in oncology · 2025Review
- The weight of time: experience of time toxicity among advanced cancer patients and their family caregivers-a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- The association of health care contact days with economic measures in the CCTG LY.12 trial.The oncologist · 2025Article
- Time Toxicity: Quantifying Healthcare Utilization Attributable to Pediatric Home Ventilation.Pediatric pulmonology · 2025Article
- Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials.JAMA network open · 2025Article
- "The biggest challenge is there's never a routine": a qualitative study of the time burdens of cancer care at home.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Time toxicity in cancer care: A concept analysis using Walker and Avant's method.Asia-Pacific journal of oncology nursing · 2024Review
- Patient, Caregiver, and Clinician Perspectives on the Time Burdens of Cancer Care.JAMA network open · 2024Article
- Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit.The oncologist · 2024Article
- Home time among older adults with acute myeloid leukemia by therapy intensity.Haematologica · 2024Article
- Reporting time toxicity in prospective cancer clinical trials: A scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Trajectory of Healthcare Contact Days for Veterans With Advanced Gastrointestinal Malignancy.The oncologist · 2024Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact (""contact days'') can help contextualize expected time use with each treatment. We assessed contact days in a completed randomized clinical trial. PATIENTS AND
methodsWe conducted a secondary analysis of the CCTG LY.12 RCT that evaluated 2-3 cycles of gemcitabine, dexamethasone, and cisplatin (GDP) vs. dexamethasone, cytarabine, and cisplatin (DHAP) in 619 patients with relapsed/refractory lymphoma prior to stem cell transplant. Primary analyses reported similar response rates and survival. We calculated patient-level "contact days" by analyzing trial forms. The study period was from assignment to progression or transplant. Days without healthcare contact were considered "home days''. We compared measures of contact days across arms.
resultsThe study period was longer in the GDP arm (median 50, vs. 47 days, P = .007). Contact days were comparable in both arms (median 18 vs 19, P = 0.79), but home days were higher in the GDP arm (median 33 vs 28, P < .001). The proportion of contact days was lower in the GDP arm (34%, vs. 38%, P = .009). The GDP arm experienced more contact days related to planned outpatient chemotherapy (median, 10 vs. 8 days), but the DHAP arm experienced many more inpatient contact days (median, 11 vs. 0 days).
conclusionsMeasures of time use, such as contact days, can be extracted from RCTs. In LY.12, despite comparable oncologic outcomes, GDP was associated with fewer contact days. Such information can guide decision-making for patients with hematological cancers, who already face significant healthcare contact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.